Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
4591.T
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q3.23
N/A
-6.16
vs -9.29
Q4.23
N/A
-6.95
vs -18.87
Q1.24
N/A
-6.20
vs -4.95
Q2.24
N/A
-6.97
vs -9.39
Q3.24
N/A
-5.62
vs -6.16
Q4.24
N/A
-6.26
vs -6.95
Q1.25
N/A
-6.33
vs -6.20
Sales Growth
YoY
Current
Estimates
Q3.23
-100%
NA vs 834K
Q4.23
NA
NA vs NA
Q1.24
-100%
NA vs 62.6M
Q2.24
NA
1M vs NA
Q3.24
NA
1M vs NA
Q4.24
NA
107K vs NA
Q1.25
NA
NA vs NA
Return on Equity
QoQ
Q2.23
-8%
-0.08
vs -0.04
Q3.23
-6%
-0.06
vs -0.08
Q4.23
-7%
-0.07
vs -0.06
Q1.24
-7%
-0.07
vs -0.07
Q2.24
-8%
-0.08
vs -0.07
Q3.24
-7%
-0.07
vs -0.08
Q4.24
-8%
-0.08
vs -0.07
Q1.25
-9%
-0.09
vs -0.08
Institutionnal Ownership
Quote Panel
Key Metrics
Relative Strength
4591.T
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
No Data Available
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Ribomic Inc. discovers and develops pharmaceutical compounds using RNA aptamers in Japan. The company develops drugs for wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma, as well as separating agents for affinity purification of human IgG and Fc-fusion proteins. Ribomic Inc. was incorporated in 2003 and is headquartered in Tokyo, Japan.
JPX
Unprofitable
Unprofitable
-3.00Â ( -2.52%)
Relative Strenght
Volume Buzz
-10%
Earning Acce
No
Dist 52w H.
18%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How 4591.T compares to sector?
4591.T
-5x